



Pediatric-onset Multiple Sclerosis treatment: a multicentre observational study comparing natalizumab with fingolimod

Antonio Carotenuto¹ · Cristina Di Monaco¹ · Laura Papetti² · Giovanna Borriello³ · Elisabetta Signoriello⁴ · Camilla Masciulli⁵ · Valentina Tomassini^{6,7} · Giovanna De Luca⁶ · Antonio Ianniello⁸ · Giacomo Lus⁴ · Federica Novarella¹ · Antonio Luca Spiezia¹ · Dario Di Somma¹ · Marcello Moccia⁹ · Maria Petracca⁸ · Carmine Iacobazzo¹ · Giuseppe Servillo¹ · Emilio Portaccio⁵ · Maria Triassi³ · Maria Pia Amato⁵ · Carlo Pozzilli⁸ · Massimiliano Valeriani^{2,10,11} · Vincenzo Brescia Morra¹ · Roberta Lanzillo¹

Received: 7 June 2024 / Revised: 17 July 2024 / Accepted: 21 July 2024 / Published online: 23 August 2024
© The Author(s) 2024

Abstract

Background Pediatric-onset Multiple Sclerosis (POMS) patients show more inflammatory disease compared with adult-onset MS. However, highly effective treatments are limited with only fingolimod being approved in Italy and natalizumab prescribed as off-label treatment.

Objectives to compare the efficacy of natalizumab versus fingolimod in POMS.

Methods This is an observational longitudinal multicentre study including natalizumab- and fingolimod-treated POMS patients (N-POMS and F-POMS, respectively). We collected Annual Relapse Rate (ARR), Expanded Disability Status Scale (EDSS), Symbol Digit Modality Test (SDMT), and MRI activity at baseline (T0), 12–18 months (T1), and last available observation (T2).

Results We enrolled 57 N-POMS and 27 F-POMS patients from six Italian MS Centres. At T0, N-POMS patients showed higher ARR ($p=0.03$), higher EDSS ($p=0.003$) and lower SDMT ($p=0.04$) at baseline compared with F-POMS. Between T₀ and T₁ ARR improved for both N-POMS and F-POMS ($p<0.001$), while EDSS ($p<0.001$) and SDMT ($p=0.03$) improved only for N-POMS. At T₂ (66.1 ± 55.4 months) we collected data from 42 out of 57 N-POMS patients showing no further ARR decrease.

Conclusion Both natalizumab and fingolimod showed high and sustained efficacy in controlling relapses and natalizumab also associated to a disability decrease in POMS. This latter effect might be partly mediated by the high inflammatory activity at baseline in N-POMS.

Keywords Multiple Sclerosis · natalizumab · fingolimod · pediatric multiple sclerosis · disease modifying treatment · real-worldstudy

Introduction

Multiple Sclerosis (MS) is a chronic immune-mediated inflammatory disease of the central nervous system. While MS primarily affects young adults, with an incidence peak between 20 and 40 years, it presents before the age of 18 in approximately 3–10% of cases [1]. The natural history of Pediatric-Onset Multiple Sclerosis (POMS) markedly differs from that of adult-onset MS (AOMS), with POMS showing greater inflammatory activity, reflected in higher relapse rate and accelerated accumulation of new Magnetic Resonance

Imaging (MRI) lesions, compared with AOMS [2–7]. Differently from AOMS, POMS cases typically exhibit a slower progression toward significant disability though they reach key disability milestones approximately 10 years earlier than AOMS patients [2].

The risk of disability decreases significantly in individuals promptly treated with high-efficacy Disease-Modifying Therapies (DMTs) [8]. The therapeutic management of patients with POMS is challenging due to the difficulty to perform randomized controlled trials assessing the efficacy and safety in children of DMTs already used to treat adult patients [9]. In Europe, fingolimod is the only approved DMT by EMA and the National Regulatory Agency (AIFA)

Extended author information available on the last page of the article

for POMS, based on findings from PARADIGMS trial [10]. In this trial, fingolimod was proven to be effective in reducing relapse rate, new MRI lesions, and brain atrophy accrual over a 2-year period vs interferon beta 1a. Other high-efficacy DMTs (e.g., natalizumab) are prescribed exclusively as off-label treatment given the efficacy and safety profile of the drug reported from observational and prospective real-world data.

Published observational studies reporting off-label natalizumab usage consistently demonstrate the efficacy of natalizumab in reducing disease activity in POMS, including those with aggressive disease, without significant adverse effects [11–13]. However, natalizumab can be prescribed to POMS patients in whom the use of fingolimod is contraindicated, has not been tolerated or has not been shown to be effective, and with specific criteria (two or more disabling relapses in the last year, and 1 or more gadolinium-enhancing lesions on brain MRI or with a significant increase in lesion load at T2 compared to a previous MRI performed at least three months apart [14]). Furthermore, natalizumab is associated with a higher risk of progressive multifocal leukoencephalopathy, caused by the JC virus [15]. Therefore, clinicians are usually cautious to prescribe natalizumab in those patients with higher Anti-JC virus antibodies titres.

Studies comparing prescription patterns of natalizumab and fingolimod in clinical settings (i.e., patients population addressed to either fingolimod or natalizumab) or comparing treatment effectiveness are still lacking. Different real-world studies comparing long-term and short-term safety and efficacy between the two drugs in the adult population have reported contrasting results, with some studies showing a trend favoring natalizumab [16–20]. A recent study analyzing data from three MS registries showed that natalizumab had higher efficacy compared with fingolimod in AOMS patients [21]. Considering the scarcity of available data in the pediatric population, we conducted a multicentre longitudinal observational study in Italy to describe the use of available high-efficacy therapies in POMS. The objective is to evaluate clinical utilization of fingolimod and natalizumab in real-world settings and to compare the efficacy of the two drugs accounting for the possible selection biases.

Methods

This is a multicentre longitudinal retrospective study. We included POMS patients from 6 Italian MS Centres (1.Federico II University, Naples; 2. Bambino Gesù Hospital IRCCS, Rome; 3. Sapienza University of Rome, Rome; 4. University of Campania, Naples; 5.University of Florence, Florence; 6. SS. Annunziata University Hospital, Chieti), satisfying the following inclusion criteria: (1) MS diagnosis according to Krupp criteria [22] (2) POMS with treatment

with natalizumab or fingolimod start before 18 years of age; (3) age at last available follow-up < 25 years old; (4) patients starting on fingolimod (F-POMS) or natalizumab (N-POMS) treatment with at least 12 month of follow-up; (5) body weight between 50 and 100 kg allowing a standard treatment dosage; (6) no other major systemic, psychiatric or neurologic diseases. POMS patients treated with both fingolimod and natalizumab in sequence were included only for the DMT started earlier (see Fig. 1).

Standard protocol approvals, registrations, and patient consents

Approval was received from the ‘Comitato Etico Campania 3’ (approval number:0023943). All subjects and parents, when necessary, gave written informed consent prior to study participation. The study was performed in accordance with good clinical practices and the Declaration of Helsinki.

Clinical assessment

We retrospectively included patients treated with natalizumab and fingolimod, with at least two clinical assessment 12–18 months apart: at baseline corresponding treatment start (T_0) and after 12–18 months (T_1). Since natalizumab has been used for longer time in clinical settings, we also collected clinical and radiologic data up to the last available assessment (T_2) for N-POMS.

Patients treated with natalizumab received intravenous 300 mg administration of natalizumab each 28 days. Patients treated with fingolimod received oral 0.5 mg per day.

At T_0 we recorded clinical and demographic data (mandatory data: age, sex, disease duration expressed in months, number of previous disease modifying treatments, previous DMT, reasons for switching from previous disease modifying treatments, annualized relapse rate, Expanded Disability Status Scale (EDSS) [23]; Pediatric Multiple Sclerosis Severity Score (Ped-MSSS) [24]; supplemental data: lesion load based on conventional T2-weighted MRI scan [low if < 10 lesions; medium if lesions number between 10 and 25; high if lesions > 25] assessed from neurologists involved in the study with demonstrated expertise in reviewing MRI images as for conventional radiologic reporting systems [25], contrast-enhancing lesions [yes/no], symbol digit modality test (SDMT) [26], JCV positivity [yes/no]). At T_1 and T_2 we recorded the following clinical data: time from previous assessment, EDSS, relapse occurrence and time to relapse, occurrence of DMT switch, time to DMT switch and reason for DMT switch (inefficacy, tolerability [lack of adherence to drug administration protocol for personal choice or willingness of different mode of administration], safety concerns), lesion load based on conventional T2-weighted

MRI scan (low if < 10 lesions; medium if lesions number between 10 and 25; high if lesions > 25), contrast-enhancing lesions (yes/no), SDMT, JCV positivity (yes/no). MRI activity was defined based on the radiologic report provided from the radiologist blinded to patients' treatment. MRI activity was defined either as contrast-enhancing lesion and/or new/enlarging T2 lesions at follow-up scans.

Statistical analysis

Statistical analyses were performed using the Stata software (version 13; StataCorp LP, College Station, TX). Demographic, clinical and radiologic features of study subjects are presented as means, medians or proportions as appropriate. All demographic, clinical and laboratory variables were checked for normality using the Shapiro–Wilk normality test. Differences between F-POMS and N-POMS for demographic and clinical features at T_0 were assessed through *t*-Test, Mann–Whitney *U* or Chi-squared as appropriate.

Paired-Samples *t* test or Wilcoxon matched-paired signed-rank test was used to compare Annual Relapse Rate (ARR), EDSS and SDMT among different time points for each drug.

We performed a propensity score (PS) matching analysis accounting for possible differences in clinic-demographic variables at T_0 in the two arms to explore natalizumab or fingolimod associated with relapse occurrence or DMT switching over the follow-up.

Specifically, to balance observed covariates (i.e., age, sex, EDSS, Ped-MSSS, ARR and number of previous treatment) between F-POMS and N-POMS we employed the PS method. A Binary Logistic Regression Model, with treatment group as dependent variable, was applied for the calculation of the PS. The PS was calculated as the predicted probability of occurrence of the event (treatment group allocation). To obtain two groups not differing for considered covariates we performed a 1-to-1 matching with no replacement methods using a caliper of 0.2 as maximum PS score distance to match groups. We applied the matching technique instead of the adjusting PS technique as to be more conservative. Using the created groups we performed analysis of survival by Cox Regression model, for time to DMT switch and time to first relapse occurrence. A *p* value < 0.05 was considered statistically significant. Results are presented with 95% confidence interval (95%CI) or *p* values.

Data availability

The anonymised dataset used and analyzed during the current study is available from the corresponding author upon reasonable request.

Results

Clinical and MRI measures at baseline

Demographic and clinical data from subjects enrolled in the study are summarized in Table 1. We included 84 MS patients (27 patients treated with fingolimod [disease duration (mean \pm SD): 16.3 ± 26.1 months] and 57 patients treated with natalizumab [disease duration: 13.5 ± 15.4 months]). Compared with F-POMS, N-POMS showed higher number of total relapse before T_0 (median [range]: 2 [0–10] vs 1 [1–6], *p* = 0.02), higher ARR before T_0 (1 [0–5.2] vs 1 [0.1–4.4], *p* = 0.03), higher EDSS at T_0 (median [range]: 2 [0–6] vs 1.5 [0–3.5], *p* = 0.003), higher Ped-MSSS [mean \pm SD: 7.2 ± 2.9 vs 5.2 ± 3.2 , *p* = 0.005], higher prevalence of patients switching from previous DMT due to inefficacy (72% vs 37%, *p* = 0.02) and lower SDMT ((mean \pm SD): 49.4 ± 7.9 vs 60.2 ± 9.2 , *p* = 0.04).

Clinical and MRI measures at T_1

Overall, patients were followed-up for a mean follow-up time at T_1 of 13.9 ± 3.8 months with no differences in follow-up time between F-POMS and N-POMS (*p* = 0.95). Between T_0 and T_1 , the percentage of patients switching to another DMT was not different between F-POMS (3 out of 27 [11.1%]) and N-POMS (6 out of 57 [10.5%]) (*p* = 0.93). F-POMS mostly switched for inefficacy () compared with N-POMS, who mostly switched for safety concerns due to JCV antibody positivity (2 out of 3 F-POMS vs 5 out of 6, *p* = 0.13). Time to first DMT switch was not different between the two groups (*p* = 0.76).

Both F-POMS and N-POMS showed ARR reduction between T_0 and T_1 (F-POMS: 1 [0.1–4.4] vs 0 [0–0.1], *p* < 0.001; N-POMS: 1 [0–5.2] vs 0 [0–0.2], *p* < 0.001). Eight out of 27 F-POMS (30%) and 8 out of 57 (14%) N-POMS experienced at least one relapse between T_0 and T_1 (*p* = 0.09). Time to first relapse was not different between the two groups (*p* = 0.76). Two N-POMS patients switched to fingolimod after 6 and 11 months from T_0 because of JCV sieroconversion. None of the F-POMS switched to natalizumab.

F-POMS did not show EDSS change between T_0 and T_1 (1.5 [0–3.5] vs 1.5 [0–2.5], *p* = 0.56). Conversely, N-POMS showed EDSS reduction between T_0 and T_1 (2 [0–6] vs 2 [0–6], *p* < 0.001). MRI data at T_1 were available for 73 out of 81 patients. Five out of 21 (23.8%) F-POMS and 11 out of 52 (21.2%) N-POMS showed MRI activity between T_0 and T_1 (*p* = 0.80). Finally, only 1 out of 5 F-POMS performed a SDMT assessment at T_1 showing thus changes were not assessed whereas 7 out of 8

Table 1 Demographic and clinical features for the enrolled patients

| | Fingolimod | Natalizumab | <i>p</i> value |
|--|-----------------|-----------------|----------------|
| Subjects | 27 | 57 | |
| Center | | | |
| Federico II University, <i>N</i> (%) | 7 (26) | 20 (35) | |
| University of Florence, <i>N</i> (%) | 2 (7) | 2 (3) | |
| University of Campania, <i>N</i> (%) | 4 (15) | 6 (10) | |
| Hospital Bambino Gesù, <i>N</i> (%) | 9 (34) | 18 (32) | |
| University of Rome ‘La Sapienza’, <i>N</i> (%) | 2 (7) | 9 (17) | |
| Sant’ Annunziata University Hospital, <i>N</i> (%) | 3 (11) | 2 (3) | |
| Sex | | | |
| Female, <i>N</i> (%) | 19 (70) | 40 (70) | 0.98 |
| Male, <i>N</i> (%) | 8 (30) | 17 (30) | |
| Age, mean \pm SD (years) | 16.2 \pm 2.7 | 15.6 \pm 2 | 0.26 |
| Age of onset, mean \pm SD (years) | 14.3 \pm 3.4 | 14 \pm 2.3 | 0.71 |
| Age of diagnosis, mean \pm SD (years) | 14.9 \pm 3.3 | 14.4 \pm 2.2 | 0.54 |
| Disease duration, mean \pm SD (month) | 16.3 \pm 26.1 | 13.5 \pm 15.4 | 0.54 |
| EDSS, median (range) | 1.5 (0–3.5) | 2 (0–6) | 0.003 |
| Ped-MSSS, mean \pm SD | 5.2 \pm 3.2 | 7.2 \pm 2.9 | 0.005 |
| Number of relapse pre T_0 , median (range) | 1 (1–6) | 2 (0–10) | 0.02 |
| ARR pre T_0 , median (range) | 1 (0.1–4.4) | 1 [0–5.2] | 0.03 |
| N° Previous DMT T_0 , median (range) | 1 (0–2) | 1 (0–2) | 0.38 |
| Previous DMT T_0^a | | | |
| Interferon, <i>N</i> (%) | 14 (87) | 25 (86) | 0.06 |
| Glatiramer acetate, <i>N</i> (%) | 1 (6.5) | | |
| Dimethyl fumarate, <i>N</i> (%) | 1 (6.5) | 3 (10) | |
| Mitoxantrone, <i>N</i> (%) | | 1 (4) | |
| Reason for switch | | | |
| Inefficacy, <i>N</i> (%) | 6 (37) | 21 (72) | 0.02 |
| Tollerability, <i>N</i> (%) | 10 (63) | 8 (28) | |
| Safety concerns, <i>N</i> (%) | | | |
| MRI lesion load ^b | | | |
| Low, <i>N</i> (%) | 3 (12) | 9 (17) | 0.77 |
| Medium, <i>N</i> (%) | 12 (44) | 21 (39) | |
| High, <i>N</i> (%) | 12 (44) | 24 (44) | |
| MRI contrast enhancement ^c | | | |
| Yes, <i>N</i> (%) | 14 (58) | 40 (78) | 0.07 |
| No, <i>N</i> (%) | 10 (42) | 11 (22) | |
| JCV status ^d | | | |
| Positive, <i>N</i> (%) | 10 (53) | 7 (15) | 0.002 |
| Negative, <i>N</i> (%) | 9 (47%) | 39 (85) | |
| SDMT T0, mean \pm SD ^e | 60.2 \pm 9.2 | 49.4 \pm 7.9 | 0.04 |

DMT Disease modifying treatment, EDSS Expanded disability status scale, Ped-MSSS Paediatric Multiple Sclerosis Severity Score, SD standard deviation, SDMT Symbol Digit Modality Test

(a) over total patients switching treatment; (b) data available for 81 patients; (c) data available for 75 patients; (d) data available for 65 patients (e) data available for 13 patients;

*Chi-squared, t test or Wilcoxon rank-sum as appropriate

N-POMS performed a SDMT assessment at T_1 showing increase in the SDMT score (48.4 ± 8.1 vs 54.2 ± 5.7 , $p=0.03$).

Propensity score matching analysis

After PS matching, we included 42 POMS patients in the analysis (21 F-POMS and 21 N-POMS). Groups were

comparable for age ($p=0.96$), gender ($p=0.52$), ARR at T_0 ($p=0.89$), EDSS at T_0 ($p=0.62$), Ped-MSSS ($p=0.64$) and number of previous DMT at T_0 ($p=1.0$). Clinical features of patients included in the analysis following PS-matching are reported in Table 2. The time to first relapse occurrence as well as time to DMT switch was not different between the two groups ($p=0.17$ [see Fig. 1] and $p=0.85$, respectively).

Clinical and MRI measures at T_2 for N-POMS

Forty-two out of 57 N-POMS patients were followed-up at T_2 with a mean follow-up time of 66.1 ± 55.4 months. Between T_1 and T_2 , 9 out of 42 (21%) N-POMS switched to another DMTs after mean time of 64.4 ± 39.4 months with 8 patients switching for safety concerns and 1 patients switching for inefficacy. Seven out of 42 (17%) N-POMS experienced at least one relapse between T_1 and T_2 after 71.5 ± 47.2 months. EDSS and ARR did not change between T_1 and T_2 . MRI data at T_2 were available for 37 out of 42 patients. Eight out of 37 (22%) N-POMS showed MRI activity between T_1 and T_2 . Finally, we collected SDMT from 5 out of 7 N-POMS who already performed SDMT assessment at T_1 and no changes were observed ($p=0.79$). Over the follow-up none of the patient experienced any serious adverse event including PML, hospitalization due to relapse severity or infections.

Discussion

In this study, we investigated the efficacy of fingolimod and natalizumab in POMS in a multicentre setting. We reported that overall natalizumab was prescribed to patients with much higher disease activity. Notwithstanding this bias in patient selection, over the follow-up both natalizumab and fingolimod were able to control the ARR as well as the EDSS, and SDMT. The beneficial effect of natalizumab on clinical outcomes was also confirmed longitudinally. However, if groups were balanced for disease severity at baseline, the two DMTs showed comparable efficacy profiles over time.

The first finding concerns the attitude of neurologists in prescribing natalizumab to POMS patients with greater disease activity, forecasting higher disability risks over the follow-up. Specifically, in our cohort, N-POMS showed higher relapse rate, physical and cognitive disability and mostly switched from previous DMTs due to inefficacy. Previous reports in AOMS have already shown that clinicians are usually more prone in prescribing natalizumab instead of fingolimod in highly active patients notwithstanding fingolimod shows a better ease of use (oral vs intravenous administration) and a lesser extent of life-threatening adverse event (i.e., progressive multifocal leucoencephalopathy) [16, 21].




Fig. 1 Analysis of time to relapse: Cox regression analysis after propensity score matching showing no differences in time to first relapse between N-POMS and F-POMS

In a recent registry-based study, the same attitude was also demonstrated for POMS and, hence, our study is in line with the report [27, 28]. However, the reason underpinning such attitude is still unclear. In clinical settings, natalizumab was proven to be more effective in controlling fatigue with a better patients' perception vs fingolimod [28, 29]. Possibly, clinicians also consider these aspects and their impact on the overall disability, and, thus, tend to prescribe more often natalizumab in those patients with higher risk of disability accrual over the follow-up.

In addition, natalizumab was proven to be able to rapidly promote disability improvement after clinical relapses possibly through rapid resolution of acute inflammation allowing proper repair actions [30]. It was also demonstrated that delayed natalizumab start was associated with increases relapse frequency and motor disability [31–33]. These factors might provide rationale for selecting natalizumab over fingolimod treatment in POMS with more severe disease onset.

Another aspect that might drive clinicians to use natalizumab over fingolimod in patients with more severe disease activity is the treatment efficacy profile. In both adults and pediatric MS patients, previous studies evaluating treatment efficacy for fingolimod and natalizumab suggested an out-performance of the latter in halting disability accrual and disease flares over the follow-up [16–19].

However, these studies also highlight the difference for clinical and demographic baseline features for patients in the two groups, suggesting caution should be taken when interpreting or planning a randomized clinical trial. To overcome the lack of a randomized clinical trial, statistical tools could be applied to assess treatment efficacy in real-world setting, adjusting analyses for baseline features between groups. PS matching is the most frequently used among

Table 2 Demographic and clinical features for patients included in the propensity-score matched analysis according to treatment allocation

| | T0 | | p value* | T1 | | p value ** | T2 | p value *** |
|-----------------------------------|--------------------------|-------------------------|-----------|----------------|------------|------------|----------------|-------------|
| | Fingolimod | Natalizumab | | Fingolimod | p value ** | | | |
| Subjects | 27 | 57 | | 27 | | 57 | – | 42 |
| Age at T ₀ , mean ± SD | 16.2 ± 2.7 | 15.6 ± 1.9 | 0.26 | | | | | |
| Sex | | | | | | | | |
| Female, N (%) | 19 (70) | 40 (70) | 0.98 | 19 (70) | – | 40 (70) | – | 31 (16) |
| Male, N (%) | 8 (30) | 17 (30) | | 8 (30) | – | 17 (30) | – | 11 (84) |
| EDSS, median (range) | 1.5 (0–3.5) | 2 (0–6) | 0.003 | 1.5 (0–2.5) | 0.56 | 2 (0–6) | p < 0.001 | 2 (0–7) |
| ARR, median (range) | 1 (0.1–4.4) | 1 (0–5.2) | 0.03 | 0 (0–0.1) | p < 0.001 | 0 (0–0.2) | p < 0.001 | 0 (0–0.005) |
| SDMT, mean ± SD | 60.2 ± 9.2 ^a | 49.4 ± 7.9 ^b | 0.04 | – | – | 54.2 ± 5.7 | 0.03 | 55 ± 7.6 |
| | T0-PS adjusted | | p value * | T1-PS adjusted | | p value ** | T2-PS adjusted | p value *** |
| | Fingolimod | | | Fingolimod | | | Natalizumab | |
| Subjects | 21 | 21 | | 21 | – | 21 | – | 17 |
| Age at T ₀ , mean ± SD | 15.9 ± 2.8 | 15.9 ± 1.8 | 0.96 | – | – | – | – | – |
| Sex | | | | | | | | |
| Female, N (%) | 14 (67) | 12 (57) | 0.52 | 14 (67) | – | 12 (57) | – | 11 (65) |
| Male, N (%) | 7 (33) | 9 (43) | | 7 (33) | – | 9 (43) | – | 6 (35) |
| EDSS, median (range) | 1.5 (0–3.5) | 1.5 (0–3) | 0.62 | 1.5 (0–2.5) | 0.98 | 1 (0–2.5) | 0.18 | 1.5 (0–7) |
| ARR, median (range) | 1 (0.3–4.4) | 1 (0.5–3.2) | 0.89 | 0 (0–0.01) | < 0.001 | 0 (0–0.01) | < 0.001 | 0 (0–0.001) |
| Ped-MSSS, mean ± SD | 5.7 ± 3.0 | 5.3 ± 2.9 | 0.64 | – | – | – | – | – |
| SDMT, mean ± SD | 60.5 ± 10.6 ^c | 48.3 ± 1.5 ^d | 0.11 | – | – | 51 ± 1.4 | 0.11 | – |

EDSS Expanded Disability Status Scale, Ped-MSSS Paediatric Multiple Sclerosis Severity Score, SD standard deviation, SDMT Symbol Digit Modality Test, ARR Annualizes Relapse Rate

* Chi-squared, t test or Wilcoxon rank-sum as appropriate

** Paired t test or Wilcoxon rank-sum as appropriate compared to T0

*** Paired t test or Wilcoxon rank-sum as appropriate compared to T1

(a) data available for five patients; (b) data available for 8 patients; (c) data available for four patients; (d) data available for three patients

these tools allowing the definition of subgroups from larger groups with a balance for selected variables. This score has been widely applied in many therapeutic areas, including MS, to adjust for the uncontrolled assignment of treatment in observational studies [34]. As we already demonstrated in adults [16], when accounting for clinical features at baseline, natalizumab and fingolimod exert similar effect in modifying disease activity and, hence, could be used in a similar clinical landscape. Indeed, when evaluating the switch from platform therapies in patients with active disease, natalizumab is more effective than fingolimod in adult MS patients [35].

Finally, we also demonstrated the long-term efficacy of natalizumab in POMS. Specifically, natalizumab showed sustained efficacy in reducing disability accrual and relapse occurrence up to 5 years. Treatment with fingolimod was previously associated with favorable outcomes in adult-onset multiple sclerosis patients [36] as well as in POMS [37–40] as assessed through randomized clinical trials. On the other hand, we do not have proper randomized

clinical trial assessing the efficacy of natalizumab vs fingolimod in POMS in the long run. This prevents natalizumab from being approved by regulatory agencies as treatment for POMS. To circumvent this shortage, several real-world studies highlighting the sustained efficacy of natalizumab are accumulating [12, 16–18, 27]. Therefore, to not necessarily prescribe natalizumab as an off-label treatment when considering natalizumab treatment as first line therapy in POMS, even below 12 years of age, our data would further support the drug-approval process from regulatory agencies. In addition, besides intravenous treatment, natalizumab could be prescribed as subcutaneous administration in adult patients after 1 year of intravenous infusion, reducing the burden for clinical facilities needed to administer infusion treatment.

We do acknowledge that this study is not without limitations. First, while this is a longitudinal study, given the retrospective nature of the study, previously collected data might not be complete and recorded in a systematic way. Furthermore, while the multicentre nature of the study allows the

possibility of enrolling a larger sample size, this would also carry greater variability in data collection ad clinicians' behavior in treatment prescription. Indeed, while the study is multicentre in nature, enrolling centres are tertiary centres where usually more severe cases are addressed. Hence, our findings might not reflect the attitude of clinicians toward less severe cases. Second, we relied on clinicians' evaluation for radiologic report of the MRI activity without a centralized MRI assessment. Since no specific MRI protocols were defined, data might not be uniform throughout participating centres. Similarly, SDMT assessment was not a standard procedure for the study and, consequently, we only collected few data on the cognitive status of the patients. This led to the absence of valuable information on the effect of natalizumab and fingolimod on cognitive function in POMS. Finally, although PS is a powerful tool to correct for group differences in terms of clinic-demographic variables, differently from randomization, it might lack a proper group balance for unobserved variables.

In conclusion, in our study, we observed that clinicians usually prescribe natalizumab more frequently than fingolimod in POMS patients showing higher inflammatory activity. Natalizumab showed a greater effect in controlling relapses and reducing disability in POMS, although this effect seems to be mostly attributable to the high inflammatory activity of patients treated with natalizumab. Therefore, it might be valuable to select natalizumab over fingolimod in patients with more severe inflammatory activity. Indeed, when balancing group for disease-specific features, the two treatments showed the same efficacy profile. Finally, we reported that natalizumab showed a sustained beneficial effect in the long run, without safety concerns in POMS, thus, adding further finding in support of the approval process for the natalizumab treatment in young patients.

Funding Open access funding provided by Università degli Studi di Napoli Federico II within the CRUI-CARE Agreement. None.

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Declarations

Conflicts of interest AC has received research grants from Almirall, research grants from ECTRIMS-MAGNIMS and honoraria from Almirall, Biogen, Roche, Sanofi-Genzyme, Merck, Ipsen and Novartis. MM has received research grants from the ECTRIMS-MAGNIMS, the UK MS Society, and Merck; honoraria from Biogen, BMS Celgene, Ipsen, Janssen, Merck, Novartis, Roche, and Sanofi-Genzyme. MP has received research grants from Italian MS Foundation and Baroni Foundation, honoraria from HEALTH&LIFE S.r.l. and Biogen and sponsorship for travel/meeting expenses from Novartis, Roche and Merck. RL has received honoraria from Biogen, Merck, Novartis, Roche, and Teva. VBM has received research grants from the Italian MS Society, and Roche, and honoraria from Bayer, Biogen, Merck, Mylan, Novartis, Roche, Sanofi-Genzyme, and Teva. MV has received grants by Biogen, Roche, Lusofarmaco and Angelini. ALS, CDM, FN, DDS, CI, GS, LP, GDL, CM, MT have nothing to disclose. VT has received

research and travel support and honoraria from the Biogen, BMS Celgene, Janssen, Merck, Novartis, Roche, Sanofi-Genzyme Almirall, Viatris, Lundbeck. Carlo Pozzilli has served on scientific advisory boards for Bristol Meyer, Novartis, Merck, Biogen, Roche, Janssen, Alexion, Almirall and has received research support from Merck, Biogen, Bristol Meyer, Novartis and Roche. AI received consulting fees from Janssen. ES received personal compensation from Almirall, Biogen, Sanofi, Novartis, Roche, Horizon, Alexion, Merck, Mylan and Teva for traveling and advisory boards. GB received honoraria and consulting fees from Almirall, Biogen, BMS, Janssen, Merck, Novartis, Sanofi and Roche. GL received speaker honoraria and/or consultancy from Biogen, Teva, Genzyme, Merck, Novartis, Almirall and Roche. EP received compensation for travel grants, participation in advisory board and/or speaking activities from Biogen, Merck Serono, Sanofi, Teva, and Novartis; serves on the editorial board of *Frontiers in Neurology and Brain Sciences*. MPA served on scientific advisory boards for and has received speaker honoraria and research support from Biogen Idec, Merck Serono, Bayer Schering Pharma, and Sanofi Aventis, and serves on the editorial board of *Multiple Sclerosis Journal* and *BMC Neurology*.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

References

1. Jeong A, Oleske DM, Holman J (2019) Epidemiology of pediatric-onset multiple sclerosis: a systematic review of the literature. *J Child Neurol* 34:705–712. <https://doi.org/10.1177/0883073819845827>
2. Renoux C, Vukusic S, Mikaeloff Y et al (2007) Natural history of multiple sclerosis with childhood onset. *N Engl J Med* 356:2603–2613. <https://doi.org/10.1056/NEJMoa067597>
3. Yeh EA, Weinstock-Guttman B, Ramanathan M et al (2009) Magnetic resonance imaging characteristics of children and adults with paediatric-onset multiple sclerosis. *Brain* 132:3392–3400. <https://doi.org/10.1093/brain/awp278>
4. Fadda G, Brown RA, Longoni G et al (2018) MRI and laboratory features and the performance of international criteria in the diagnosis of multiple sclerosis in children and adolescents: a prospective cohort study. *Lancet Child Adolesc Health* 2:191–204. [https://doi.org/10.1016/S2352-4642\(18\)30026-9](https://doi.org/10.1016/S2352-4642(18)30026-9)
5. Jakimovski D, Awan S, Eckert SP et al (2022) Multiple sclerosis in children: differential diagnosis, prognosis, and disease-modifying treatment. *CNS Drugs* 36:45–59. <https://doi.org/10.1007/s40263-021-00887-w>
6. Ghezzi A, Deplano V, Faroni J et al (1997) Multiple sclerosis in childhood: clinical features of 149 cases. *Mult Scler* 3:43–46. <https://doi.org/10.1177/135245859700300105>
7. Iaffaldano P, Portaccio E, Lucisano G et al (2024) Multiple sclerosis progression and relapse activity in children. *JAMA Neurol* 81:50–58. <https://doi.org/10.1001/jamaneurol.2023.4455>
8. Baroncini D, Simone M, Iaffaldano P et al (2021) Risk of persistent disability in patients with pediatric-onset multiple sclerosis.

- JAMA Neurol 78:726–735. <https://doi.org/10.1001/jamaneurol.2021.1008>
9. Ghezzi A, Amato MP, Edan G et al (2021) The introduction of new medications in pediatric multiple sclerosis: open issues and challenges. Mult Scler 27:479–482. <https://doi.org/10.1177/1352458520930620>
10. Chitnis T, Arnold DL, Banwell B et al (2018) Trial of fingolimod versus interferon beta-1a in PEDIATRIC MULTIPLE SCLEROSIS. N Engl J Med 379:1017–1027. <https://doi.org/10.1056/NEJMoa1800149>
11. Saponaro AC, Tully T, Maillart E et al (2023) Treatments of paediatric multiple sclerosis: efficacy and tolerance in a longitudinal follow-up study. Eur J Paediatr Neurol 45:22–28. <https://doi.org/10.1016/j.ejpn.2023.05.001>
12. Baroncini D, Ghezzi A, Guaschino C et al (2022) Long-term follow-up (up to 11 years) of an Italian pediatric MS cohort treated with Natalizumab: a multicenter, observational study. Neurol Sci 43:6415–6423. <https://doi.org/10.1007/s10072-022-06211-8>
13. Ghezzi A, Pozzilli C, Grimaldi LM et al (2010) Safety and efficacy of natalizumab in children with multiple sclerosis. Neurology 75:912–917. <https://doi.org/10.1212/WNL.0b013e3181f11daf>
14. Determina (2020) n. 142638/2020. GU Serie Generale n.322
15. Langer-Gould A, Atlas SW, Green AJ et al (2005) Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 353:375–381. <https://doi.org/10.1056/NEJMoa051847>
16. Lanzillo R, Carotenuto A, Moccia M et al (2017) A longitudinal real-life comparison study of natalizumab and fingolimod. Acta Neurol Scand 136:217–222. <https://doi.org/10.1111/ane.12718>
17. Koch-Henriksen N, Magyari M, Sellebjerg F et al (2017) A comparison of multiple sclerosis clinical disease activity between patients treated with natalizumab and fingolimod. Mult Scler 23:234–241. <https://doi.org/10.1177/1352458516643393>
18. Boziki M, Bakirtzis C, Giantz V et al (2021) Long-Term Efficacy Outcomes of Natalizumab vs. Fingolimod in Patients With Highly Active Relapsing-Remitting Multiple Sclerosis: Real-World Data From a Multiple Sclerosis Reference Center. Front Neurol 12:699844. <https://doi.org/10.3389/fneur.2021.699844>
19. Cohen M, Mondot L, Bucciarelli F et al (2021) BEST-MS: a prospective head-to-head comparative study of natalizumab and fingolimod in active relapsing MS. Mult Scler 27:1556–1563. <https://doi.org/10.1177/1352458520969145>
20. Prosperini L, Sacca F, Cordioli C et al (2017) Real-world effectiveness of natalizumab and fingolimod compared with self-injectable drugs in non-responders and in treatment-naïve patients with multiple sclerosis. J Neurol 264:284–294. <https://doi.org/10.1007/s00415-016-8343-5>
21. Andersen JB, Sharmin S, Lefort M et al (2021) The effectiveness of natalizumab vs fingolimod-A comparison of international registry studies. Mult Scler Relat Disord 53:103012. <https://doi.org/10.1016/j.msard.2021.103012>
22. Krupp LB, Tardieu M, Amato MP et al (2013) International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions. Mult Scler 19:1261–1267. <https://doi.org/10.1177/1352458513484547>
23. Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33:1444–1452. <https://doi.org/10.1212/wnl.33.11.1444>
24. Santoro JD, Waltz M, Aaen G et al (2020) Pediatric Multiple Sclerosis Severity Score in a large US cohort. Neurology 95:e1844–e1853. <https://doi.org/10.1212/WNL.0000000000010414>
25. Scaravilli A, Tranfa M, Pontillo G et al (2024) Radiological Reporting Systems in Multiple Sclerosis. Appl Sci 14:5626
26. Benedict RH, DeLuca J, Phillips G et al (2017) Validity of the Symbol Digit Modalities Test as a cognition performance outcome measure for multiple sclerosis. Mult Scler 23:721–733. <https://doi.org/10.1177/1352458517690821>
27. Spelman T, Simoneau G, Hyde R et al (2024) Comparative effectiveness of natalizumab, fingolimod, and injectable therapies in pediatric-onset multiple sclerosis: a registry-based study. Neurology 102:e208114. <https://doi.org/10.1212/WNL.000000000000208114>
28. Foley J, Berkovich R, Gudesblatt M et al (2023) Characterizing the “feel-good experience” in multiple sclerosis patients treated with natalizumab or other therapies. Neurodegener Dis Manag 13:23–34. <https://doi.org/10.2217/nmt-2022-0003>
29. Svensson A, Falk E, Celius EG et al (2013) Natalizumab treatment reduces fatigue in multiple sclerosis. Results from the TYNERGY trial; a study in the real life setting. PLoS ONE 8:e58643. <https://doi.org/10.1371/journal.pone.0058643>
30. Belachew S, Phan-Ba R, Bartholome E et al (2011) Natalizumab induces a rapid improvement of disability status and ambulation after failure of previous therapy in relapsing-remitting multiple sclerosis. Eur J Neurol 18:240–245. <https://doi.org/10.1111/j.1468-1331.2010.03112.x>
31. Jafarpour S, Pinto S, Vu MH et al (2024) Delayed initiation of disease modifying therapy increases relapse frequency and motor disability in pediatric onset multiple sclerosis. Mult Scler Relat Disord 87:105669. <https://doi.org/10.1016/j.msard.2024.105669>
32. Abdel-Mannan OA, Manchoon C, Rossor T et al (2021) Use of disease-modifying therapies in pediatric relapsing-remitting multiple sclerosis in the United Kingdom. Neurol Neuroimmunol Neuroinflamm. <https://doi.org/10.1212/NXI.0000000000001008>
33. Krysko KM, Graves JS, Rensel M et al (2020) Real-world effectiveness of initial disease-modifying therapies in pediatric multiple sclerosis. Ann Neurol 88:42–55. <https://doi.org/10.1002/ana.25737>
34. Trojano M, Pellegrini F, Paolicelli D et al (2009) Observational studies: propensity score analysis of non-randomized data. Int MS J 16:90–97
35. Kalincik T, Horakova D, Spelman T et al (2015) Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis. Ann Neurol 77:425–435. <https://doi.org/10.1002/ana.24339>
36. Cohen JA, Khatri B, Barkhof F et al (2016) Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study. J Neurol Neurosurg Psychiatry 87:468–475. <https://doi.org/10.1136/jnnp-2015-310597>
37. Arnold DL, Banwell B, Bar-Or A et al (2020) Effect of fingolimod on MRI outcomes in patients with paediatric-onset multiple sclerosis: results from the phase 3 PARADIGMS study. J Neurol Neurosurg Psychiatry 91:483–492. <https://doi.org/10.1136/jnnp-2019-322138>
38. Borriello G, Pozzilli C (2021) Long-term fingolimod treatment in two pediatric patients with multiple sclerosis. Neurol Sci 42:29–36. <https://doi.org/10.1007/s10072-021-05116-2>
39. Krupp L, Banwell B, Chitnis T et al (2022) Effect of fingolimod on health-related quality of life in paediatric patients with multiple sclerosis: results from the phase 3 PARADIGMS Study. BMJ Neurol Open 4:e000215. <https://doi.org/10.1136/bmjno-2021-000215>
40. Deiva K, Huppke P, Banwell B et al (2020) Consistent control of disease activity with fingolimod versus IFN beta-1a in paediatric-onset multiple sclerosis: further insights from PARADIGMS. J Neurol Neurosurg Psychiatry 91:58–66. <https://doi.org/10.1136/jnnp-2019-321124>

Authors and Affiliations

Antonio Carotenuto¹ · Cristina Di Monaco¹ · Laura Papetti² · Giovanna Borriello³ · Elisabetta Signoriello⁴ · Camilla Masciulli⁵ · Valentina Tomassini^{6,7} · Giovanna De Luca⁶ · Antonio Ianniello⁸ · Giacomo Lus⁴ · Federica Novarella¹ · Antonio Luca Spiezio¹ · Dario Di Somma¹ · Marcello Moccia⁹ · Maria Petracca⁸ · Carmine Iacovazzo¹ · Giuseppe Servillo¹ · Emilio Portaccio⁵ · Maria Triassi³ · Maria Pia Amato⁵ · Carlo Pozzilli⁸ · Massimiliano Valeriani^{2,10,11} · Vincenzo Brescia Morra¹ · Roberta Lanzillo¹

✉ Antonio Carotenuto
carotenutoantonio87@gmail.com

¹ Department of Neuroscience, Reproductive Science and Odontostomatology, Multiple Sclerosis Clinical Care and Research Centre, Federico II University, Naples, Italy

² Developmental Neurology Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy

³ Department of Public Health, University "Federico II" of Naples, Naples, Italy

⁴ Second Division of Neurology, Department of Advanced Medical and Surgical Sciences, University of Campania, Naples, Italy

⁵ Department of NEUROFARBA, University of Florence, Florence, Italy

⁶ Multiple Sclerosis Centre, Clinical Neurology, SS. Annunziata University Hospital, Chieti, Italy

⁷ Institute for Advanced Biomedical Technologies (ITAB), Department of Neurosciences, Imaging and Clinical Sciences, University G. d'Annunzio of Chieti-Pescara, Chieti, Italy

⁸ Department of Human Neurosciences, Sapienza University, Rome, Italy

⁹ Department of Molecular Medicine and Medical Biotechnology, Federico II University of Naples, Naples, Italy

¹⁰ System Medicine Department, Tor Vergata University of Rome, Rome, Italy

¹¹ Center for Sensory-Motor Interaction, Aalborg University, Aalborg, Denmark

Terms and Conditions

Springer Nature journal content, brought to you courtesy of Springer Nature Customer Service Center GmbH (“Springer Nature”). Springer Nature supports a reasonable amount of sharing of research papers by authors, subscribers and authorised users (“Users”), for small-scale personal, non-commercial use provided that all copyright, trade and service marks and other proprietary notices are maintained. By accessing, sharing, receiving or otherwise using the Springer Nature journal content you agree to these terms of use (“Terms”). For these purposes, Springer Nature considers academic use (by researchers and students) to be non-commercial.

These Terms are supplementary and will apply in addition to any applicable website terms and conditions, a relevant site licence or a personal subscription. These Terms will prevail over any conflict or ambiguity with regards to the relevant terms, a site licence or a personal subscription (to the extent of the conflict or ambiguity only). For Creative Commons-licensed articles, the terms of the Creative Commons license used will apply.

We collect and use personal data to provide access to the Springer Nature journal content. We may also use these personal data internally within ResearchGate and Springer Nature and as agreed share it, in an anonymised way, for purposes of tracking, analysis and reporting. We will not otherwise disclose your personal data outside the ResearchGate or the Springer Nature group of companies unless we have your permission as detailed in the Privacy Policy.

While Users may use the Springer Nature journal content for small scale, personal non-commercial use, it is important to note that Users may not:

1. use such content for the purpose of providing other users with access on a regular or large scale basis or as a means to circumvent access control;
2. use such content where to do so would be considered a criminal or statutory offence in any jurisdiction, or gives rise to civil liability, or is otherwise unlawful;
3. falsely or misleadingly imply or suggest endorsement, approval , sponsorship, or association unless explicitly agreed to by Springer Nature in writing;
4. use bots or other automated methods to access the content or redirect messages
5. override any security feature or exclusionary protocol; or
6. share the content in order to create substitute for Springer Nature products or services or a systematic database of Springer Nature journal content.

In line with the restriction against commercial use, Springer Nature does not permit the creation of a product or service that creates revenue, royalties, rent or income from our content or its inclusion as part of a paid for service or for other commercial gain. Springer Nature journal content cannot be used for inter-library loans and librarians may not upload Springer Nature journal content on a large scale into their, or any other, institutional repository.

These terms of use are reviewed regularly and may be amended at any time. Springer Nature is not obligated to publish any information or content on this website and may remove it or features or functionality at our sole discretion, at any time with or without notice. Springer Nature may revoke this licence to you at any time and remove access to any copies of the Springer Nature journal content which have been saved.

To the fullest extent permitted by law, Springer Nature makes no warranties, representations or guarantees to Users, either express or implied with respect to the Springer nature journal content and all parties disclaim and waive any implied warranties or warranties imposed by law, including merchantability or fitness for any particular purpose.

Please note that these rights do not automatically extend to content, data or other material published by Springer Nature that may be licensed from third parties.

If you would like to use or distribute our Springer Nature journal content to a wider audience or on a regular basis or in any other manner not expressly permitted by these Terms, please contact Springer Nature at

onlineservice@springernature.com